The Case Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1826-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.case.edu/cancer
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Early Phase 1
Recruiting
- Conditions
- Allogeneic Hematopoietic Cell Transplantation
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04332341
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Phase 2
Terminated
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04322643
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
Phase 1
Active, not recruiting
- Conditions
- Basal Cell Carcinoma of the Head and Neck
- Interventions
- Other: Tissue collection
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT04323202
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Early Phase 1
Withdrawn
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04285749
Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma
Not Applicable
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Other: Palliative CareOther: FACT-MM questionnaireOther: HADS questionnaire
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04248244
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
Active, not recruiting
- Conditions
- DCISInvasive Breast Cancer
- Interventions
- Other: Stool sampleOther: Skin Swab Sample
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT04245150
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases
Phase 2
Recruiting
- Conditions
- Spine Stereotactic Radiosurgery (sSRS)Spine Metastases
- Interventions
- Device: Diagnostic MRIDevice: Planning MRIOther: Simulation CTOther: QOL assessmentOther: Brief pain inventory (BPI)Radiation: sSRS in 1 fractionRadiation: sSRS in 2 fraction
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT04218617
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer
Not Applicable
Withdrawn
- Conditions
- HR-positive Breast Cancer
- Interventions
- Other: Blood collectionDietary Supplement: Vitamin B12Other: Brief Pain Inventory - Short Form surveyOther: FACT-ES Trial Outcome Index (Version 4)Other: Questionnaire to Assess Adherence to Aromatase InhibitorsOther: Demographics Questionnaire
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04205786
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Phase 2
Withdrawn
- Conditions
- Recurrent Endometrial Cancer
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04197219
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
Not Applicable
Active, not recruiting
- Conditions
- MyelomaStem Cell Transplant ComplicationsLymphomaAllogeneic and Autologous Stem Cell Transplant
- Interventions
- Other: physical therapy consultOther: Cognitive AssessmentOther: Cancer Aging Research Group (CARG) assessmentOther: Medication ReviewOther: Nutrition assessmentOther: Laboratory studiesOther: Patient satisfaction questionnaireOther: Physician QuestionnaireOther: Patient follow-up questionnaire
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04194840
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath